A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.
An Open Multicentre Phase III Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Severe Haemophilia A.
The main objectives of this study are: - to assess Optivate® consumption (IU/kg consumed per month for prophylactic and on-demand therapy and dose at each bleed). - to assess clinical outcome when treating a bleed with Optivate®. - to evaluate Optivate® in terms of clinical tolerance and safety in children under the age of 6 years. . - to assess FVIII inhibitor development during the study.
Consumption of FVIII
Optivate® (Human Coagulation Factor VIII)
Study Arms / Comparison Groups
Description: Optivate® (Human Coagulation Factor VIII)
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Primary Completion Date
Inclusion Criteria: - Children under the age of 6 years with a diagnosis of severe Haemophilia A. Subjects who required FVIII therapy and did not demonstrate inhibitors to FVIII. Children with history of inhibitors to FVIII or clinically significant renal or liver disease were not eligible to participate in the study. Exclusion Criteria: -
N/A - 6 Years
Accepts Healthy Volunteers
Bio Products Laboratory